Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf, iPSC-derived cellular immunotherapies for cancer and immune disorders. The company's platform generates master engineered iPSC lines that can be differentiated into NK cells, T cells, and other immune effector cells, targeting hematologic malignancies and solid tumors. With minimal revenue ($0.0B TTM, down 78.5% YoY) and high cash burn ($100M+ annually), FATE is a pure R&D play dependent on clinical trial outcomes and partnership deals.
FATE operates a pre-commercial business model focused on advancing iPSC-derived cell therapy candidates through clinical trials. Revenue generation is currently limited to upfront payments, research funding, and milestone achievements from strategic partnerships. The company's value proposition centers on its proprietary iPSC platform enabling off-the-shelf allogeneic cell therapies (no patient-specific manufacturing), potentially offering cost and scalability advantages versus autologous CAR-T therapies. Monetization will ultimately depend on successful clinical validation, regulatory approvals, and either commercialization partnerships or building internal commercial infrastructure. Current 100% gross margin reflects minimal COGS on collaboration revenue, while -1543% operating margin indicates pure cash consumption phase.
Clinical trial data readouts for lead programs (FT596 NK cell therapy for B-cell malignancies, FT522 for solid tumors) - positive efficacy/safety data drives significant volatility
FDA regulatory interactions and IND clearances for new programs or trial expansions
Strategic partnership announcements, licensing deals, or equity financing events given cash burn rate
Competitive developments in allogeneic cell therapy space (CRSP, BEAM, BLUE) affecting sector sentiment
Cash runway updates and financing needs - with $100M+ annual burn and 7.87x current ratio, dilution risk is material
Clinical trial failure risk - iPSC-derived allogeneic cell therapies face unproven efficacy and safety profiles versus established autologous CAR-T. Any serious adverse events or lack of durable responses could invalidate entire platform
Regulatory pathway uncertainty - FDA has limited precedent for iPSC-derived products, creating risk of unexpected requirements, delays, or rejection
Manufacturing complexity and scalability - iPSC differentiation and quality control at commercial scale remains unproven, with potential for batch failures or cost overruns
Reimbursement uncertainty - payers may resist coverage for off-the-shelf cell therapies without clear cost-effectiveness versus existing treatments
Autologous CAR-T incumbents (GILD's Kite, BMY's Breyanzi) have established efficacy and are improving manufacturing speed, potentially negating FATE's off-the-shelf advantage
Allogeneic competitors (CRSP, BEAM, ALLO) pursuing alternative approaches (gene editing, base editing) may achieve superior persistence and efficacy
Large pharma in-house cell therapy programs could leverage greater resources and commercial infrastructure
Cash burn sustainability - with -$100M operating cash flow and minimal revenue, company faces recurring dilution risk. At current burn rate, existing cash may provide 12-18 months runway, necessitating near-term financing
Equity dilution risk - $200M market cap limits ability to raise meaningful capital without severe shareholder dilution. Down-round financing could trigger death spiral
Partnership dependency - loss of existing collaborations or failure to secure new deals would accelerate cash depletion and force program cuts
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, financing environment for unprofitable biotech is highly sensitive to risk appetite, which correlates with economic conditions. During recessions, venture capital and public market funding for clinical-stage companies contracts significantly, creating existential risk for cash-burning entities.
High sensitivity through multiple channels: (1) Valuation - biotech DCF models heavily weight distant cash flows, making them extremely sensitive to discount rates. Rising rates compress NPV of pipeline assets. (2) Financing costs - while current 0.34x debt/equity is modest, future capital raises become more expensive in high-rate environments. (3) Opportunity cost - investors rotate from speculative growth to safer yield alternatives when risk-free rates rise. (4) Cash management - higher rates provide better returns on $155M+ cash balance (implied from 7.87x current ratio).
Minimal direct credit exposure as business model doesn't involve lending or credit-dependent customers. However, access to capital markets is critical - credit spread widening (high yield OAS expansion) signals risk-off environment that severely impacts ability to raise equity or debt financing. Tight credit conditions have historically correlated with biotech sector underperformance and increased bankruptcy risk for pre-revenue companies.
growth/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from successful clinical development. Typical holders include biotech-focused hedge funds, venture capital crossover funds, and retail speculators. Not suitable for value or income investors given negative earnings, no dividends, and binary clinical outcomes. Recent 37% 3-month rally suggests momentum traders are active, likely driven by sector rotation or specific catalyst anticipation.
high - Clinical-stage biotech with binary event risk exhibits extreme volatility. Stock can move 30-50%+ on single data readouts. Beta likely exceeds 1.5x relative to broader market. Low market cap ($200M) and limited institutional ownership amplify price swings. Illiquidity can create gap risk around news events.
